Drug General Information (ID: DDI1ZRTD9E)
Drug Name			Human adenovirus e serotype 4 strain cl-68578 antigen		Drug Info		Emapalumab		Drug Info
Drug Type		Vaccine				Monoclonal antibody
Therapeutic Class		Vaccine				Selective Immunosuppressants

Mechanism of Human adenovirus e serotype 4 strain cl-68578 antigen-Emapalumab Interaction (Severity Level: Major)
Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph
Drug Name		Human adenovirus e serotype 4 strain cl-68578 antigen				Emapalumab
Mechanism		Vaccine or toxoid				Immunosuppressive effects
Key Mechanism Factor 1
		Factor Name		Vaccine/toxoid
		Factor Description		The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response.
Mechanism Description		Antagonize the effect of Human adenovirus e serotype 4 strain cl-68578 antigen when combined with Emapalumab

Recommended Action
Management		The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.

References
1	Product Information. Gamifant (emapalumab). Sobi Inc, Ardmore, PA.